Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low O <sup>6</sup> ‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours

3 Dec 2008

Abstract excerpt

CONTEXT: Recent case reports detail the successful use of temozolomide in the management of aggressive pituitary tumours. O(6)-methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that counteracts the effect of temozolomide. OBJECTIVE: To study MGMT expression in pituitary tumours and consider whether MGMT expression is associated with response to temozolomide therapy in aggressive pituitary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Glioma Diagnosis and Treatment
Share to Pituitary Gland Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19067722
DOI: 10.1111/j.1365-2265.2008.03487.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low O <sup>6</sup> ‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumoursPMID 19067722Read ↗

Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O<sup>6</sup>-Methylguanine Methyltransferase (MGMT) Promoter Methylation and ExpressionSemantic proximity Read ↗

The role of temozolomide in the treatment of aggressive pituitary tumors.Semantic proximity Read ↗

Pituitary tumours: findings from whole genome analysesSemantic proximity Read ↗

MGMT methylation: A marker of response to temozolomide in low‐grade gliomasSemantic proximity Read ↗

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomideSemantic proximity Read ↗

Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.Semantic proximity Read ↗

O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agentsSemantic proximity Read ↗

Sensitivity to temozolomide of cell lines derived from brain tumours and melanomas: relationship to MGMT gene expressionSemantic proximity Read ↗

A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.Semantic proximity Read ↗

Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenomaSemantic proximity Read ↗

Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine NeoplasmsSemantic proximity Read ↗

Deoxyribonucleic Acid Methyltransferase 3B Promotes Epigenetic Silencing through Histone 3 Chromatin Modifications in Pituitary CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.